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Summary
What is known and objective: It has been suggested that pyridoxine has an antilacto-
genic effect. Studies of the efficacy of pyridoxine in suppressing lactation have re-
ported conflicting results. The aim of this review was to evaluate the effectiveness and 
safety of high- dose pyridoxine in post- partum lactation inhibition.
Methods: This systematic review included published trials that compared the efficacy 
and/or safety of pyridoxine to placebo or to other pharmacological agents for the in-
hibition of post- partum lactation. We searched PubMed, Embase, ScienceDirect, 
CINAHL,	AMED,	the	Cochrane	library	and	the	clinical	trials	registry	to	identify	relevant	
literature. No limit was imposed on the year of publication of the studies, and the re-
view included studies published until 15 January 2016. Two reviewers independently 
extracted data and assessed the risk of bias.
Results and discussion: Seven studies were included, with a total of 1155 women, of 
which 471 women received pyridoxine. Three studies were randomized controlled 
trials,	whereas	the	remaining	four	studies	were	non-	randomized	controlled	trials.	All	of	
the included studies were relatively small (n=18- 482). The studies compared pyridox-
ine with placebo, bromocriptine and/or stilboestrol. Pyridoxine was given orally, with 
a total daily dose of 450- 600 mg for 5- 7 days. Two trials (n=349 participants) indi-
cated that pyridoxine was effective in inhibiting lactation in approximately 95% of the 
enrolled	patients.	All	other	studies	failed	to	demonstrate	pyridoxine	efficacy	through	
either clinical assessment or prolactin level measurements. Pyridoxine safety was as-
sessed by two trials in which no serious untoward side effects were reported. Overall, 
the risk of bias for most of the studies was low to moderate.
What is new and conclusion: Current evidence supporting the effectiveness of high- 
dose pyridoxine in the inhibition of post- partum lactation is inconsistent and insuffi-
cient. Larger randomized trials are needed to confirm the efficacy of pyridoxine in 
post- partum lactation inhibition.
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1  | WHAT IS KNOWN AND OBJECTIVE
Although	the	benefits	of	breastfeeding	for	mothers	and	infants	are	well	
documented,1-3 under some conditions, lactation suppression might be 
indicated for the best interest of the lactating mother and/or the infant. 
Some of the medical conditions that contraindicate breastfeeding include 
infants with the metabolic disorder classic galactosemia, mothers who are 
positive for human T- cell lymphotrophic virus type I or II, and untreated 
brucellosis, among others.1,2,4	Furthermore,	 the	 lactating	mother’s	use	
of some types of medications might necessitate avoiding breastfeeding, 
such as mothers undergoing chemotherapy.1,2 Lactation inhibition might 
also be needed following an infant death or miscarriage.5,6
When the decision to suppress lactation or not breastfeed an in-
fant is made, the prevention of breast engorgement is essential to 
avoid associated complications, such as breast pain and mastitis.5-7 
Up to one- third of women who do not breastfeed and use non- 
pharmacological approaches, such as brassieres, binders, or ice packs, 
or analgesics to treat symptoms associated with lactation suppres-
sion may experience severe breast pain.8 Several pharmacological 
agents for lactation inhibition have been studied. Oestrogen prepara-
tions given either alone or in combination with androgens have been 
shown to be effective in 40%- 100% of women; however, due to their 
high rates of rebound lactation and the associated increased risk of 
thrombosis and pulmonary embolism, the use of these preparations 
is discouraged.9 The dopamine agonists (bromocriptine and cabergo-
line) have also been reported to be effective in inhibiting puerperal 
lactation.9,10 However, the use of dopamine agonists is not recom-
mended in the presence of hypertensive disorders of pregnancy, in-
cluding pre- eclampsia, eclampsia, pregnancy- induced hypertension 
and post- partum hypertension, or in women with a history of pu-
erperal psychosis.11,12 Similarly, variable results were reported with 
other agents, such as clomiphene, prostaglandin E, serotonin antago-
nists and pyridoxine.9
Pyridoxine (ie vitamin B6) has been shown to have an antilacto-
genic effect.13 The exact mechanism by which pyridoxine inhibits lac-
tation is not well understood. However, pyridoxine is known to act as 
a co- enzyme that promotes the conversion of dopa to dopamine. The 
increase in dopamine formation in hypothalamic neurons and their 
major dendrites is thought to result in prolactin inhibition and con-
sequent lactation inhibition.14 Studies of the efficacy of pyridoxine in 
lactation suppression have reported conflicting results.14,15
No systematic review explicitly investigated the efficacy and safety 
of pyridoxine for post- partum lactation suppression. The objective of 
this systematic review was to evaluate the effectiveness and safety of 




of pyridoxine to placebo or to other pharmacological agents for the 
inhibition of post- partum lactation were included in this review. 
However, reviews, letters, conference papers and abstracts were ex-
cluded. Studies that evaluated pyridoxine efficacy in women who had 
already established lactation and trials published in languages other 
than English were also excluded from the review.
2.2 | Outcome measures
Studies that described any of the following efficacy and/or safety out-
comes were evaluated: suppression of lactation, as indicated by clinical 
assessment, breast pain, engorgement and/or milk secretion (or as de-
scribed by the trial), prolactin level and adverse events related to pyri-
doxine. The words “inhibition” and “suppression” of lactation were used 
interchangeably in this review to refer to the inhibition or suppression 
of lactation during the early period before lactation is established.
2.3 | Search strategy
We	 searched	 PubMed,	 Embase,	 ScienceDirect,	 CINAHL,	 AMED,	
the Cochrane library and the clinical trials registry to identify rel-
evant literature. The key search terms that were used to identify 
relevant studies were “pyridoxine,” “vitamin B6,” “lactation,” “breast-
feeding,” “breast milk,” “inhibition,” “suppression,” “prevention” and 
“stop.” The search terms were used in various combinations along 
with truncations (*) and relevant Boolean operators, depending on 
the	database.	Furthermore,	manual	searches	of	the	references	of	the	
identified articles were performed to identify additional articles that 
were not retrieved through the electronic searches. The search was 
limited to studies that included human subjects and were published 
in English. No limit was imposed on the year of publication of the 
studies, and the review included studies published as recently as 15 
January 2016.
2.4 | Data extraction and management
RefWorks, which is a web- based reference management software 
program, was used to manage the retrieved references.16 The primary 
reviewer (DS) conducted the initial search of the databases. This was 
followed by screening of the titles and abstracts of the retrieved arti-
cles by another reviewer (SS). The screening was validated by a second 
reviewer	(AA)	to	ensure	the	comprehensiveness	and	relevance	of	the	
search.	Full-	text	articles	of	studies	that	were	judged	to	be	potentially	
eligible	 during	 the	 title/abstract	 screening	 were	 retrieved.	 Finally,	
two authors (DS, SS) independently reviewed the full- text articles to 
ensure	 their	 suitability	 for	 inclusion.	Any	disagreements	 in	 the	pro-
cess	were	resolved	through	consensus.	For	the	included	studies,	data	
were	 extracted	 independently	 by	 two	 of	 the	 authors	 (DS,	 SS).	 Any	
disagreements were resolved through discussion and adjudication by 
a	 third	 reviewer	 (AA)	whenever	necessary.	A	 standardized	data	 ex-
traction	tool	was	developed	utilizing	PRISMA	items.17 The extracted 
data were presented under the following headings: reference (author, 
year), objective, study design, population, intervention, comparator, 
outcome	measures	and	key	results.	All	extracted	data	were	validated	
for accuracy through double entry by two authors.
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2.5 | Quality assessment
All	included	studies	were	assessed	independently	by	two	authors	to	de-
termine the risk of bias. Discrepancies were resolved through consen-
sus. Randomized trials were assessed using the criteria outlined in the 
Cochrane risk of bias tool for Randomized Control Trials (RCTs).18 Risk 
assessment classifies each criterion of bias assessment into low risk, 
high risk or unclear risk within the study and across the studies. Non- 
randomized interventional studies were assessed using the criteria of the 
Risk Of Bias In Non- randomized Studies—of Interventions (ROBINS- I) 
tool.19 Risk assessment classifies each criterion of bias assessment into 
five categories: low risk, moderate risk, serious risk, critical risk and no 
information.	For	reasons	of	practicality,	the	five	categories	were	merged	
into three categories (low- to- moderate risk, serious- to- critical risk and 
unclear risk), which were used for bias assessment within and across 
studies.
3  | RESULTS
3.1 | Characteristics of the included studies
Of the 2552 search results that were retrieved, seven studies13-15,20-23 
were	considered	to	be	eligible	for	inclusion	in	the	review	(Figure	1).	
These studies included a total of 1155 participants, of which 471 
women received pyridoxine. Three studies were randomized con-
trolled trials (Table 1),14,15,20 whereas the remaining four studies were 
non- randomized controlled trials (Table 2)13, 21-23. The specific study 
 designs of the non- randomized studies were not clearly defined in the 
articles. None of the included studies presented evidence of power 
analysis (ie sample size calculations); the largest study included a total 
of 482 participants, and four of the studies included less than 100 
participants. Six studies were published in the 1970s,13-15,21-23 and 
only one study was published in the 1980s20 (Table 1 and Table 2).
3.2 | Participants
Generally, the studies recruited post- partum women who did not 
breastfeed or had contraindications for breastfeeding. The partici-
pants’ obstetric characteristics (eg parity and gestational week at de-
livery) were not described in any of the studies, and exclusion criteria 
were not specified in many of the studies.
3.3 | Interventions
The studies compared pyridoxine with placebo, bromocriptine 
and/or stilboestrol. Pyridoxine was compared with placebo in four 
F IGURE  1 Search strategy diagram
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TABLE  1 Characteristics of the included randomized studies [ordered by date of publication]
Marcus RG, 1975
Objective To assess the efficacy of pyridoxine in the inhibition of lactation
Design/methodology Randomized controlled double- blind trial
Population Women on the first day of puerperium 
N=95




Outcome measures Breast discomfort, breast consistency, untoward side effects
Results • No significant differences in discomfort and breast consistency between the groups
• Pyridoxine inhibited lactation in 96% of patients compared with 76.5% of control patients (p<0.02)




Criterion Authors’ judgement Support for judgement
Sequence generation Unclear risk Method of sequence generation not stated. “The patients were randomly selected”
Allocation	concealment Unclear risk No information about allocation concealment was provided
Blinding Low risk It was mentioned that the trial was “double blind” and “carried out with two identical 
tablets.” It is unlikely that the blinding could have been broken, so the risk of bias for both 
efficacy and safety parameters was low
Incomplete outcome data Low risk “Two of the records were spoilt and 95 patients were therefore studied”
Selective outcome reporting Low risk Results of all prespecified outcomes were reported
Other sources of bias Low risk The study appears to be free of other sources of bias
Macdonald HN et al., 1976
Objective To assess pyridoxine effectiveness in the suppression of puerperal lactation
Design/Methodology Randomized controlled double- blind trial
Population Puerperal women wishing to bottle feed within the first 24 h of delivery 
N=175
Intervention Pyridoxine 200 mg 3 times per day for 6 d 
N=93
Control Placebo (Lactose) 
N=82
Outcome measures Breast discomfort, leakage of milk, breast engorgement
Results • No significant differences were demonstrated between the pyridoxine and placebo groups, whether assessed 
based on subjective discomfort, objective engorgement or the persistence of lactation
Others – 
Risk of bias
Criterion Authors’ judgement Support for judgement
Sequence generation Unclear risk Method of sequence allocation was not mentioned. Tablets were issued “in random order”
Allocation	concealment Low risk The hospital pharmacy dispensed numbered packs containing identical tablets of either 
lactose or pyridoxine, and retained the identifying code until completion of the study
Blinding Low risk The trial was double- blind and carried out with two identical tablets. It is unlikely that the 
blinding could have been broken, so the risk of bias was low
(Continues)
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studies and with other pharmacological agents (bromocriptine 
or stilboestrol) in four studies. One trial compared women who 
received pyridoxine to suppress lactation to normally lactating 
women. Pyridoxine was administered orally in all of the studies, and 
the total daily dose ranged between 450 and 600 mg for 5- 7 days. 
The treatment was commenced shortly after delivery in all of the 
enrolled women.
3.4 | Outcome measures
The method of outcome assessment varied among the studies. Two 
studies assessed the effect of high- dose pyridoxine use on prolac-
tin levels,21,23 whereas pyridoxine efficacy was evaluated clinically 
in six of the studies.13-15,20-22 However, different parameters were 
used to describe clinical efficacy, including breast discomfort, breast 
Risk of bias
Criterion Authors’ judgement Support for judgement
Incomplete outcome data High risk Of 191 randomized patients, 175 patients completed inpatient treatment (8.4% were 
excluded).	Fourteen	patients	withdrew,	as	they	discharged	themselves	early	from	the	
hospital (nine in the pyridoxine group, five in the placebo group), one patient decided to 
breastfeed and one patient was withdrawn for skin rash. 
Of 191 randomized patients, 131 patients completed outpatient questionnaires (31.4% 
were excluded); 77% of the 82 patients on placebo replied in comparison with 73% of the 
93 patients on pyridoxine
Selective outcome reporting Low risk Results of all prespecified outcomes were reported
Other sources of bias Low risk The study appears to be free of other sources of bias
Boes EG, 1980
Objective To compare the efficacy of pyridoxine with that of bromocriptine in lactation inhibition
Design/Methodology Randomized controlled double- blind trial
Population Non- breastfeeding mothers requiring suppression of lactation during the post- partum period 
N=97
Intervention Pyridoxine 200 mg 3 times per day for 6 d, with 1 placebo tablet 3 times per day from day 7- 14 (for blinding 
purposes) 
N=48
Control Bromocriptine 2.5 mg 2 times per day for 14 d, with 1 placebo tablet daily for 14 d (for blinding purposes) 
N=49
Outcome measures Milk secretion, mammary congestion, side effects
Results • Successful suppression of lactation appeared to be achieved in 29 of the 48 patients in the pyridoxine group and 
in all 49 patients receiving bromocriptine (P<0.001)
• No major side effects were recorded. One patient in the pyridoxine group stopped the medication due to nausea 
on the eleventh day, after she had been using the inactive tablets for 5 d
Others Ergometrine 1 tablet 3 times per day for 3 d was prescribed routinely during the puerperal period
Risk of bias
Criterion Authors’ judgement Support for judgement
Sequence generation Unclear risk Method of sequence allocation was not mentioned. Patients were randomly assigned to the 
groups
Allocation	concealment Unclear risk No sufficient information about allocation concealment. It was mentioned that the  
tablets were packed in identical bubble packs, and the ward nurse checked that the  
tablets were taken in the right order. However, this information was not sufficient  
to judge whether patients or investigators could foresee  
assignment
Blinding Unclear risk Insufficient information to permit judgement concerning whether the ward nurse and doctor 
were blinded regarding efficacy and safety parameters
Incomplete outcome data Low risk Of the 100 patients admitted to the trial, data were available for 97 patients. Two patients, 
one from each group, left the hospital within 24 h of starting treatment, and 1 patient form 
did not reach the statistician (3% excluded after randomization)
Selective outcome reporting Low risk Results of all prespecified outcomes were reported
Other sources of bias Low risk The study appears to be free of other sources of bias
TABLE  1  (Continued)
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TABLE  2 Characteristics of the included non- randomized intervention studies [ordered by date of publication]
Foukas M, 1973
Objective To evaluate the efficacy of pyridoxine in the suppression of lactation in puerperal patients
Design/Methodology Placebo- controlled, double- blind trial
Population Puerperal patients in their second or third day after delivery. Women with deficiency or failure of lactation were excluded. 
N=254
Intervention Pyridoxine 200 mg 3 times per day for 6 d 
  N=75 (blinded) 
Pyridoxine 200 mg 3 times per day for 6 d 
  N=25 (not blinded)
Control Placebo 1 tablet 3 times per day for 6 ds 
  N=86 
Stilboestrol 5 mg 3 times per day for 6 d 
  N=68
Outcome measures The time of cessation of lactation
Results • Ninety-five per cent of the women treated with pyridoxine had their lactation successfully suppressed within 
1 wk, compared to 83 per cent for stilboestrol and 17 per cent for the placebo
Others After	the	second	course	of	pyridoxine,	lactation	ceased	completely	in	the	remaining	five	patients
Risk of bias
Criterion Authors’ judgement Support for judgement
Confounding Unclear risk No information concerning whether confounding might be present
Selection of participants into 
the study
Unclear risk No information is reported about the selection of participants into the study
Classification of interventions Low- to- moderate risk Interventions were well defined. Three identical tablets were used and contained a 
placebo,	5	mg	of	stilboestrol,	or	200	mg	of	pyridoxine.	A	course	of	treatment	consisted	
of one tablet three times per day for 6 d, beginning on the second or third day after 
delivery
Departures from intended 
interventions
Low- to- moderate risk Participants	adhered	to	the	assigned	interventions.	After	analysing	the	results	of	the	
assigned interventions, a second course of pyridoxine was provided to five patients 
who failed to suppress lactation
Missing data Low- to- moderate risk Of 375 questionnaires issued, seventy questionnaires were not completed, and 51 
questionnaires were inadequately filled in. The 254 patients for whom full information 
was available were divided into four groups, and all of these patients were included in 
the analysis
Measurement of outcomes Serious- to- critical risk Twenty- five patients were un- blinded to pyridoxine. These patients all (100%) ceased 
lactation	within	1	wk,	compared	to	93%	in	the	blinded	group.	A	possibility	of	influenc-
ing outcome measures due to lack of blinding was present
Selection of the reported result Low- to- moderate risk The outcome measurements and analyses are consistent with an a priori plan
Canales ES et al., 1976
Objective To investigate the influence of pyridoxine administration on prolactin release and milk production
Design/Methodology Not well stated; described as a control trial
Population Puerperal women on the first day after delivery with contraindications for breastfeeding due to medical reasons 
N=34
Intervention Pyridoxine 150 mg 3 times per day for 7 d 
N=14
Control Bromocriptine 7.5 mg daily for 7 d 
N=20
Outcome measures Serum prolactin, milk production
Results •	 All	14	women	who	received	pyridoxine	experienced	painful	breast	engorgement
• Pyridoxine had no effect on serum prolactin levels
Others – 
(Continues)
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Risk of bias
Criterion Authors’ judgement Support for judgement
Confounding Unclear risk No information concerning whether confounding might be present
Selection of participants into the study Unclear risk No information was reported about the selection of participants into the study
Classification of interventions Low- to- moderate risk The study mentioned the types of interventions that were provided for each 
group
Departures from intended interventions Low- to- moderate risk No bias due to deviation from the intended intervention
Missing data Low- to- moderate risk The	results	of	all	included	patients	were	presented.	Fourteen	puerperal	women	
received 150 mg of pyridoxine three times per day for 7 d, beginning on the 
first day after delivery. The control group of 20 puerperal women received 
7.5 mg of bromocriptine each day throughout the study period
Measurement of outcomes Low- to- moderate risk The outcome measure was expected to be minimally influenced by knowledge 
of the intervention. Serum prolactin was measured via radioimmunoassay for 
both groups
Selection of the reported result Serious- to- critical risk There	was	evidence	or	strong	suspicion	of	selective	reporting	of	results.	A	
third group of lactating women was presented in the figure but not men-
tioned in the methodology section
Felming S, 1977
Objective To compare the effectiveness of pyridoxine, stilboestrol and placebo in the inhibition of puerperal 
lactation
Design/Methodology Not well stated; double- blind trial
Population Women who had vaginal delivery with a negative history of thromboembolism and wished to suppress 
lactation 
N=482
Intervention Pyridoxine 200 mg 3 times per day for 5 d 
N=155
Control Stilboestrol 5 mg 3 times per day for 5 d 
N=165 
Sucrose 1 tablet 3 times per day for 5 d 
N=162
Outcome measures Breast tenderness, breast engorgement, lactation 
Rebound engorgement, lactation or increased lochia 6 wk post- partum
Results • Stilboestrol was significantly more effective in inhibiting the onset of lactation than pyridoxine or the 
placebo (P<0.01)
• Pyridoxine was only marginally more effective than placebo
• Regarding the incidence of rebound phenomena, results were not statistically significant (P>0.3)
• No patients reported increased lochia
Others Women were issued written advice concerning fluid restriction and the wearing of a firm brassiere. 
One patient reported calf tenderness on day 3 post- partum. The code was broken. The subject was 
found to be receiving pyridoxine, and a deep vein thrombosis was excluded
Risk of bias
Criterion Authors’ judgement Support for judgement
Confounding Serious- to- critical risk Women were issued written advice that fluid restriction and the wearing of a firm 
brassiere would assist in preventing the onset of lactation. The differences in 
applying these instructions between the different groups were not measured, which 
can confound the results
Selection of participants into 
the study
Unclear risk No information was reported about the selection of participants into the study
Classification of interventions Low- to- moderate risk Intervention status was well defined
Departures from intended 
interventions
Low- to- moderate risk No bias due to deviation from the intended intervention is expected. Women who 
received additional medications known to influence lactation (N= 14) or decided to 
breastfeed were excluded to avoid deviation from the intended intervention
TABLE  2  (Continued)
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consistency, breast engorgement and cessation of lactation. Safety 
was evaluated in only two of the studies.
Two of the included studies reported that the use of high- dose 
pyridoxine (ie 200 mg three times per day for 6 days) resulted in the 
suppression of lactation in approximately 95% of the enrolled sub-
jects.13,14 In these two studies, 193 patients received pyridoxine, which 
accounted for 41% of the total number of patients who received pyri-
doxine in all of the included studies. Efficacy was assessed clinically in 
both of these studies. However, all other studies failed to demonstrate 
pyridoxine efficacy through either clinical assessment or prolactin level 
measurements.15,20-23 No untoward side effects were reported in ei-
ther of the two studies that assessed the safety of the use of high- dose 
pyridoxine.14,20
3.5 | Quality assessment and risk of bias
The details for the risk of bias assessment for each study are pre-
sented in Table 1 and Table 2. Overall, the risk of bias for most studies 
was	low	or	low-	to-	moderate	(Figure	2	and	Figure	3).
Risk of bias
Criterion Authors’ judgement Support for judgement
Missing data Serious- to- critical risk Of the 600 patients commencing the trial, 24 patients subsequently decided to 
breast- feed, 14 patients received additional medications known to enhance lactation, 
and	11	patients	discontinued	the	trial	for	other	reasons.	For	69	patients,	the	records	
were incomplete, often because of the patient’s early discharge from the hospital. 
Thus, 482 patients comprise the subject matter of this report (19.7% were excluded)
Measurement of outcomes Low- to- moderate risk The methods of outcome assessment were comparable across intervention groups
Selection of the reported result Low- to- moderate risk The outcome measurements and analyses are consistent with an a priori plan
De Waal JM et al., 1978
Objective To determine the effect of pyridoxine administration on serum prolactin levels in post- partum women
Design/Methodology Not stated
Population Post- partum women who did not want to breastfeed 
N= 18
Intervention A	single	dose	of	pyridoxine	200	mg	immediately	post-	partum 
Then, pyridoxine 200 mg 3 times per day for 7 d 
N= 9
Control Normally lactating women 
N= 9
Outcome measures Serum prolactin levels
Results • Mean (±SD) serum prolactin levels on day 5 relative to day 1 were 53% (±29%) in the pyridoxine group and 
68% (±39%) in the control group. The difference was not statistically significant
• None of the pyridoxine-treated patients was lactation suppressed
Others Serum prolactin was measured for a third group who had drug- induced hyperprolactinemia, but analysis was 
carried out separately
Risk of bias
Criterion Authors’ judgement Support for judgement
Confounding Unclear risk No information concerning whether confounding might be present
Selection of participants into the 
study
Unclear risk No information was reported about the selection of participants into the study
Classification of interventions Low- to- moderate risk Intervention status was well defined and based solely on information collected at the 
time of intervention
Departures from intended 
interventions
Low- to- moderate risk No bias due to deviation from the intended intervention was mentioned
Missing data Low- to- moderate risk Data were reasonably complete
Measurement of outcomes Serious- to- critical risk None of the pyridoxine- treated patients was lactation suppressed. No information 
about how this outcome was measured was provided, and it is unknown if this 
outcome is a reflection of prolactin level measurements only
Selection of the reported result Low- to- moderate risk All	the	intended	and	planned	outcomes	were	presented	in	the	results
TABLE  2  (Continued)
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4  | DISCUSSION
Despite the availability of dopamine agonists (eg cabergoline and bro-
mocriptine) for use in post- partum lactation inhibition, many maternal 
medical conditions necessitate avoiding the use of these agents due 
to safety concerns. These concerns highlight the need for alternative 
effective	and	safe	agents.	A	small	number	of	studies	suggested	that	pyri-
doxine has an antilactogenic effect; however, data related to the clinical 
effectiveness and safety of pyridoxine are limited. This review evalu-
ated the effectiveness and safety of pyridoxine in post- partum lactation 
inhibition.
Foukas	was	the	first	 to	report	the	effectiveness	of	high-	dose	pyr-
idoxine in post- partum lactation suppression.13 Thereafter, Marcus 
reaffirmed that finding.14 In both studies, effectiveness was assessed 
clinically. However, all other studies failed to produce similar results 
through clinical assessment 15,20-22 or prolactin level measurements.21,23 
Similar conflicting results were reported with pyridoxine use for treating 
galactorrhoea- amenorrhoea syndromes. Initially, near the time at which 
Foukas	and	Marcus	published	their	findings,	McIntosh	suggested	a	role	
for pyridoxine in the management of women with hyperprolactinemia 
and galactorrhoea- amenorrhoea.24 Later, pyridoxine was demonstrated 
to lack effectiveness for reducing prolactin levels in these patients.25-27 
These conflicting results make it difficult to confirm the effectiveness of 
pyridoxine for clinical use in post- partum lactation inhibition.
In our review, pyridoxine safety was not a concern, as no untoward 
side effects were reported. However, the assessment of pyridoxine 
safety was limited to only two of the included studies.14,20
The studies included in the current review used varying meth-
ods to assess lactation inhibition, including clinical evaluations and/
or	laboratory	investigations.	Furthermore,	the	criteria	used	for	clinical	
evaluations of pyridoxine efficacy were also defined in different ways 
in different studies. These criteria included leakage of milk, breast en-
gorgement and the time of lactation cessation. Overall, the total num-
ber of patients who received pyridoxine was not very large (n=471 
patients), and sample size calculations were not presented in any of 
the	included	studies.	Furthermore,	the	specific	study	designs	were	not	
clearly defined in the non- randomized studies,13,21-23 and all of the 
studies included in the current review had been published for more 
than 35 years ago.13-15,20-23 Based on these observations, the strength 
of the current evidence is not sufficient to recommend the routine use 
of pyridoxine for post- partum lactation inhibition in clinical practice.
This review was limited to literature published in the English lan-
guage, and studies published in other languages were excluded, although 
such studies may contain valuable information for this review. The qual-
ity of the included studies is another limitation of this review. The study 
design was not well stated in many of the studies. We used Cochrane 
risk of bias assessment tools to evaluate how this weakness impacted 
the study quality, but the risk of bias appeared to be low to moderate.
5  | WHAT IS NEW AND CONCLUSION
The available evidence is conflicting and insufficient to confirm the 
effectiveness of high- dose pyridoxine in post- partum lactation inhibi-
tion. Limited data suggest that high- dose pyridoxine is safe in women 
who aim to inhibit lactation. However, larger and well- designed rand-
omized controlled trials are needed to reaffirm the effectiveness and 
safety of pyridoxine in post- partum lactation inhibition before recom-
mending the use of this regimen in routine clinical practice.
F IGURE  2 Risk of bias summary: review authors’ judgments for 
risk of bias for randomized controlled trials [Colour figure can be 
viewed at wileyonlinelibrary.com]














































F IGURE  3 Risk of bias summary: review authors’ judgments for 
risk of bias for non- randomized trials [Colour figure can be viewed at 
wileyonlinelibrary.com]
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